Afatinib free basefeatured
WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#:200500
CAS#:850140-72-6 (free base)
Description:Afatinib, also know as BIBW 2992, is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types. Afatinib is approved in much of the world (including the United States, Canada, the United Kingdom and Australia) for the treatment of metastatic non-small cell lung carcinoma (NSCLC), developed by Boehringer Ingelheim. It acts as an angiokinase inhibitor.
Price and Availability
Afatinib free base, purity > 98%, is in stock. The same day shipping out after order is received.
Chemical Structure
Theoretical Analysis
MedKoo Cat#: 200500Name: Afatinib free baseCAS#: 850140-72-6 (free base)Chemical Formula: C24H25ClFN5O3Exact Mass: 485.163Molecular Weight: 485.94Elemental Analysis: C, 59.32; H, 5.19; Cl, 7.30; F, 3.91; N, 14.41; O, 9.88
Related CAS #:850140-73-7 (dimaleate)439081-18-2 (free base)850140-72-6 (free base)
Synonym:BIBW-2992; BIBW 2992; BIBW2992. Afatinib free base; trade name: Gilotrif, Tomtovok and Tovok.
IUPAC/Chemical Name:(S,E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide.
InChi Key:ULXXDDBFHOBEHA-CWDCEQMOSA-N
InChi Code:InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1
SMILES Code:O=C(NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@@H]4COCC4)/C=C/CN(C)C
Technical Data
Additional Information
Related: 439081-18-2(Afatinib free base);850140-73-7 (Afatinib dimaleate)
As of July 2012, it is undergoing Phase III clinical trials for this indication and breast cancer, as well as Phase II trials for prostate and head and neck cancer, and a Phase I glioma trial. Afatinib is not a first-line treatment; it is only used after other therapies have failed. In October 2010 a Phase III trial in NSCLC patients called Lux-Lung 5 began with this drug. Fall 2010 interim results suggested the drug extended progression-free survival threefold compared to placebo, but did not extend overall survival. In May 2012, the Phase IIb/III trial Lux-Lung 1 came to the same conclusion. Phase II results for breast cancer that over-expresses the protein human epidermal growth factor receptor 2 (Her2-positive breast cancer) were described as promising by the authors, with 19 of 41 patients achieving benefit from afatinib. Double-blind Phase III trials are under way to confirm or refute this finding. Her2-negative breast cancers showed limited or no response to the drug.
References
1: Belani CP. The role of irreversible EGFRinhibitors in the treatment of non-small cell lung cancer: overcomingresistance to reversible EGFR inhibitors. Cancer Invest. 2010May;28(4):413-23. Review. PubMed PMID: 20307200.
2: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find ExpClin Pharmacol. 2009 Dec;31(10):661-700. PubMed PMID: 20140276.
3: Gazdar AF. Epidermal growth factor receptor inhibition in lungcancer: the evolving role of individualized therapy. Cancer MetastasisRev. 2010 Mar;29(1):37-48. Review. PubMed PMID: 20127143.
4: Sos ML, Rode HB, Heynck S, Peifer M, Fischer F, Klüter S, Pawar VG,Reuter C, Heuckmann JM, Weiss J, Ruddigkeit L, Rabiller M, Koker M,Simard JR, Getlik M, Yuza Y, Chen TH, Greulich H, Thomas RK, Rauh D.Chemogenomic profiling provides insights into the limited activity ofirreversible EGFR Inhibitors in tumor cells expressing the T790M EGFRresistance mutation. Cancer Res. 2010 Feb 1;70(3):868-74. Epub 2010 Jan26. PubMed PMID: 20103621.
5: Doebele RC, Oton AB, Peled N, Camidge DR, Bunn PA Jr. New strategiesto overcome limitations of reversible EGFR tyrosine kinase inhibitortherapy in non-small cell lung cancer. Lung Cancer. 2010 Jan 19. [Epubahead of print] PubMed PMID: 20092908.
6: Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A,Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK, Zakowski MF,Politi KA, Pao W. Dual targeting of EGFR can overcome a major drugresistance mutation in mouse models of EGFR mutant lung cancer. J ClinInvest. 2009 Oct;119(10):3000-10. doi: 10.1172/JCI38746. Epub 2009 Sep14. PubMed PMID: 19759520; PubMed Central PMCID: PMC2752070.
7: Ocaña A, Amir E. Irreversible pan-ErbB tyrosine kinase inhibitors andbreast cancer: current status and future directions. Cancer Treat Rev.2009 Dec;35(8):685-91. Epub 2009 Sep 4. Review. PubMed PMID: 19733440.
8: Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermalgrowth factor receptor tyrosine kinase inhibitors in non-small-cell lungcancers dependent on the epidermal growth factor receptor pathway. ClinLung Cancer. 2009 Jul;10(4):281-9. Review. PubMed PMID: 19632948; PubMedCentral PMCID: PMC2758558.
9: Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, Borgman CL,Zaghlul S, Brandstetter KA, Kubo S, Takahashi M, Chirieac LR, Padera RF,Bronson RT, Shapiro GI, Greulich H, Meyerson M, Guertler U, Chesa PG,Solca F, Wistuba II, Wong KK. HER2YVMA drives rapid development ofadenosquamous lung tumors in mice that are sensitive to BIBW2992 andrapamycin combination therapy. Proc Natl Acad Sci U S A. 2009 Jan13;106(2):474-9. Epub 2009 Jan 2. PubMed PMID: 19122144; PubMed CentralPMCID: PMC2626727.
10: Minkovsky N, Berezov A. BIBW-2992, a dual receptor tyrosine kinaseinhibitor for the treatment of solid tumors. Curr Opin Investig Drugs.2008 Dec;9(12):1336-46. Review. PubMed PMID: 19037840.
MedKoo,由化学家和药学家陈清奇博士。北卡罗莱纳州的研究三角区(ResearchTrianglePark,简称RTP),是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司,该公司的业务范围主要是为全球所有从事抗癌药物研究和开发的制药公司,高校,研究院所,政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。
中文名MedKoo中 文美帝药库医药科技公司创立于2008年总部位于美国东海岸
MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务。 MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务和分子有竞争力的价格。MedKoo是您可靠的合作伙伴采购药物发现和药物分子。 MedKoo是世界的抗癌化学试剂和激酶抑制剂供应商之一。我们制造,销售和分销用于肿瘤学研究的高质量抗癌小分子试剂。我们的使命是建立世界上全面的抗癌小分子集合。我们还为制药行业,医学研究组织和学术机构提供高质量的研究服务。我们致力于以具有竞争力的价格提供服务和分子。MedKoo是您可靠的药物发现和药物分子采购合作伙伴。 CRISPR-Cas9是近年兴起的用于靶向基因组特定位置,进行DNA修饰的重要工具。研究发现CRISPR是细菌为了应对病毒的攻击而演化而来的获得性免疫防御机制。具体来说,在CRISPR和Cas9的作用下,经由小RNA分子的引导,靶向并沉默入侵者遗传物质核酸的关键部分。在该系统中,crRNA(CRISPR-derivedRNA)与tracrRNA(trans-activatingRNA)结合形成的复合物能特异性识别靶基因序列,并引导Cas9核酸内切酶在靶定位点剪切双链DNA,随后,细胞的非同源末端连接修复机制(NHEJ)重新连接断裂处的基因组DNA,并引入插入或缺失突变。另外也可以提供一个外源双链供体DNA(Donor)通过同源重组(HR)整合进断裂处的基因组,从而达到对基因组DNA进行修饰的目的。
目前,CRISPR-Cas9系统的高效基因组编辑功能已被应用于多种生物,包括小鼠、大鼠、斑马鱼、秀丽隐杆线虫,也包含多种细菌和植物,甚至在人体上也有应用。
ebiomall.com